Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) filed a Form 8-K on March 10, 2026, to announce financial results for the fiscal year ended December 31, 2025. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1) and investor presentation materials (Exhibit 99.2), which are referenced but not included in the provided text.
Material Changes
No specific material changes versus the prior comparable period are detailed in the filing text. The document serves as a notification that results for the year ended December 31, 2025, have been issued.
Guidance, Outlook, and Risks
The company has prepared investor presentation materials intended for management use, which are attached as Exhibit 99.2. The filing explicitly states that the information in the press release and presentation materials is furnished but not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific guidance, risks, or contingencies are described in the text of the 8-K itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for 2025.
- Examine Exhibit 99.2 (Investor Presentation) for updated clinical trial timelines, pipeline milestones, and forward-looking guidance.
- Verify the company's cash runway and burn rate based on the full financial statements referenced in the press release.
- Confirm any updates to the company's emerging growth company status or accounting standard elections.